Medpace Holdings, Inc. (MEDP) — SEC Filings
Medpace Holdings, Inc. (MEDP) — 28 SEC filings. Latest: 10-Q (Oct 23, 2025). Includes 13 8-K, 6 10-Q, 3 SC 13G/A.
View Medpace Holdings, Inc. on SEC EDGAR
Overview
Medpace Holdings, Inc. (MEDP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 23, 2025: Medpace Holdings, Inc. (MEDP) reported robust financial performance for the three and nine months ended September 30, 2025. Revenue, net, increased significantly to $659.9 million for the three months ended September 30, 2025, up from $533.3 million in the prior year, representing a 23.7% increase.
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 1 bullish, 26 neutral, 1 mixed. The dominant filing sentiment for Medpace Holdings, Inc. is neutral.
Filing Type Overview
Medpace Holdings, Inc. (MEDP) has filed 6 10-Q, 13 8-K, 1 DEF 14A, 2 10-K, 1 DEFA14A, 2 SC 13D/A, 3 SC 13G/A with the SEC between Jan 2024 to Oct 2025.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of MEDP's 25 recent filings, 0 were flagged as high-risk, 6 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1.82B |
| Net Income | $316.0M |
| EPS | $10.64 |
| Cash Position | $285.4M |
| Total Assets | $1.75B |
Key Executives
- August J. Troendle
Industry Context
Medpace operates within the highly competitive global contract research organization (CRO) market, which supports pharmaceutical, biotechnology, and medical device companies in drug and device development. The industry is characterized by a trend towards outsourcing clinical trial management due to increasing complexity, regulatory hurdles, and the need for specialized expertise. Key trends include the adoption of decentralized clinical trials, advanced data analytics, and a focus on specific therapeutic areas.
Top Tags
sec-filing (6) · financials (6) · financial-reporting (4) · 10-Q (4) · material-agreement (3) · 8-k (3) · corporate-governance (3) · quarterly-report (3) · filing (3) · CRO (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Q3 2025 Net Revenue | $659.9M | Increased 23.7% from $533.3M in Q3 2024 |
| YTD Q3 2025 Net Revenue | $1.82B | Increased 15.9% from $1.57B in YTD Q3 2024 |
| Q3 2025 Net Income | $111.1M | Increased 15.2% from $96.4M in Q3 2024 |
| YTD Q3 2025 Net Income | $316.0M | Increased 9.9% from $287.4M in YTD Q3 2024 |
| Q3 2025 Diluted EPS | $3.86 | Increased from $3.01 in Q3 2024 |
| YTD Q3 2025 Diluted EPS | $10.64 | Increased from $8.96 in YTD Q3 2024 |
| YTD Q3 2025 Stock Repurchases | $917.4M | Significantly reduced cash and cash equivalents |
| Cash and Cash Equivalents | $285.4M | Decreased from $669.4M at Dec 31, 2024 |
| Advanced Billings | $834.3M | Increased by $123.7M, indicating strong future revenue |
| Remaining Performance Obligations | $3.5B | Strong backlog for active projects |
| Revenue for Q2 2025 | $525.3M | Increased from $450.1 million in Q2 2024, representing 16.7% growth. |
| Net Income for Q2 2025 | $85.7M | Increased from $72.3 million in Q2 2024, representing 18.5% growth. |
| Direct Costs for Q2 2025 | $300.5M | Increased from $260.2 million in Q2 2024, reflecting operational expansion. |
| Reimbursable Out-of-Pocket Costs for Q2 2025 | $105.1M | Increased from $90.5 million in Q2 2024, indicating higher project activity. |
| Total Assets as of June 30, 2025 | $2.1B | Increased from $1.9 billion at December 31, 2024, showing balance sheet strength. |
Forward-Looking Statements
- {"claim":"Medpace Holdings, Inc. will likely release its full Q4 2023 or annual 2023 earnings report soon, given the 'Results of Operations and Financial Condition' item.","entity":"Medpace Holdings, Inc.","targetDate":"2024-03-31","confidence":"high"}
- {"claim":"The stock price of MEDP will react to the specific financial details once they are fully disclosed, potentially showing volatility.","entity":"MEDP","targetDate":"2024-02-19","confidence":"medium"}
- {"claim":"Other institutional investors may re-evaluate their positions in Medpace Holdings, Inc. following Wasatch Advisors LP's reduced stake.","entity":"Medpace Holdings, Inc.","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Medpace Holdings, Inc. (MEDP)?
Medpace Holdings, Inc. has 28 recent SEC filings from Jan 2024 to Oct 2025, including 13 8-K, 6 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MEDP filings?
Across 28 filings, the sentiment breakdown is: 1 bullish, 26 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Medpace Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Medpace Holdings, Inc. (MEDP) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Medpace Holdings, Inc.?
Key financial highlights from Medpace Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MEDP?
The investment thesis for MEDP includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Medpace Holdings, Inc.?
Key executives identified across Medpace Holdings, Inc.'s filings include August J. Troendle.
What are the main risk factors for Medpace Holdings, Inc. stock?
Of MEDP's 25 assessed filings, 0 were flagged high-risk, 6 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Medpace Holdings, Inc.?
Recent forward-looking statements from Medpace Holdings, Inc. include guidance on {"claim":"Medpace Holdings, Inc. will likely release its full Q4 2023 or annual 2023 earnings report soon, given the 'Re and 2 other predictions.